Tiemann Investment Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Tiemann Investment Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-245	Closed	-$258K	–	200
2024 Q3	$258K	Sell	245 -5	-2%	-$5.56K	0.11%	162
2024 Q2	$263K	Hold	250	–	–	0.12%	152
2024 Q1	$241K	Hold	250	–	–	0.11%	166
2023 Q4	$220K	Buy	250 +15	+6%	+$12.4K	0.11%	173
2023 Q3	$193K	Sell	235 -50	-18%	-$39.3K	0.1%	181
2023 Q2	$205K	Sell	285 -20	-7%	-$15.4K	0.1%	183
2023 Q1	$251K	Sell	305 -5	-2%	-$3.77K	0.14%	166
2022 Q4	$224K	Buy	+310	New	+$229K	0.13%	175
2020 Q3	–	Sell	-342	Closed	-$213K	–	187
2020 Q2	$213K	Buy	+342	New	+$194K	0.15%	165
2016 Q1	–	Sell	-487	Closed	-$264K	–	156
2015 Q4	$264K	Hold	487	–	–	0.27%	120
2015 Q3	$227K	Sell	487 -10	-2%	-$5.37K	0.25%	134
2015 Q2	$254K	Hold	497	–	–	0.26%	123
2015 Q1	$224K	Buy	+497	New	+$211K	0.23%	137

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Tiemann Investment Advisors's REGN Position: Q4 2024 in Review

Tiemann Investment Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 245 shares — an estimated $258K sold.

Tiemann Investment Advisors first reported a position in REGN in Q1 2015 and held it in 13 quarters. The position peaked at $264K in Q4 2015. 1,317 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

Tiemann Investment Advisors reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Tiemann Investment Advisors sold 245 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $258K.
Tiemann Investment Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2015 and held it in 13 quarters.
Tiemann Investment Advisors's Regeneron Pharmaceuticals position peaked at $264K in Q4 2015.
1,317 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Tiemann Investment Advisors's 13F filing for Q4 2024, filed 7 Feb 2025.